Marketwire -- GHENT, Belgium, 3 October 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today announced that it has been awarded a grant worth EUR 1.8 million by the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
